Topics
CME/CE
Editorial Board
Enbrel manufacturer speaks of post-approval plan
Washington, D.C. Officials of Amgen spoke of teaching patientsabout biologic treatments of psoriasis, dermatologists spreading the wordabout the new class of drugs, and the physician-patient relationship asits Enbrel (etanercept) added to the resume leading it toward approval bythe U.S. Food and Drug Administration.
Related Videos
Related Content
